GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Orgenesis Inc.
Orgenesis is a biotech company building a decentralized platform for the production of cell and gene therapies. Its stock price is a bet that its point-of-care model can make these complex treatments more accessible.
Share prices of companies in the market segment - It med
Orgenesis Inc. is a biotech company developing a decentralized platform for producing cell and gene therapies directly in hospitals. We've categorized it as "IT in Medicine." The chart below shows how the market values companies changing the drug manufacturing model.
Broad Market Index - GURU.Markets
Orgenesis Inc. is a biotech company developing a decentralized platform for producing cell and gene therapies directly in hospitals. We've categorized it as "IT in Medicine." The chart below shows how the market values companies changing the drug manufacturing model.
Change in the price of a company, segment, and market as a whole per day
ORGS - Daily change in the company's share price Orgenesis Inc.
For Orgenesis Inc., a cell therapy company, daily volatility reflects sensitivity to partnership news. This metric is an indicator of demand for its decentralized therapeutic drug manufacturing model.
Daily change in the price of a set of shares in a market segment - It med
Orgenesis is a biotech company building a decentralized network for the development and production of cell and gene therapies. This is an innovative business model in a cutting-edge sector. The chart below illustrates the high volatility typical of this industry, providing context for evaluating ORG's stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Orgenesis is a biotech company building a decentralized network for the production of cell and gene therapies. Its innovative business model is a bet on the future of medicine. Its stock is volatile, reflecting progress in this cutting-edge field.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Orgenesis Inc.
For Orgenesis Inc., year-over-year performance tells the story of its unique business model. Its 12-month market cap reflects its success in creating a decentralized network for cell and gene therapy production. Its valuation is a bet that its point-of-care approach can make these complex treatments more accessible.
Annual dynamics of market capitalization of the market segment - It med
Orgenesis Inc. is a biotech company with a unique model focused on decentralizing cell and gene therapy production. This chart shows how its disruptive approach, hospital partnerships, and technological risks influence its volatile performance in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Orgenesis, a biotech company building a decentralized network for the production of cell and gene therapies, aims to make these complex treatments more accessible. Its year-over-year market capitalization reflects the relevance of its business model to hospitals and pharmaceutical companies.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Orgenesis Inc.
Orgenesis is a biotechnology company focused on cell and gene therapy. Its monthly performance reflects progress in deploying its decentralized manufacturing model and the success of its therapeutic programs.
Monthly dynamics of market capitalization of the market segment - It med
Orgenesis is a biotech company that is creating a decentralized platform for the development and production of cell and gene therapies directly in hospitals, making them more accessible. The graph below shows the overall dynamics in the medical IT and biotech sectors, reflecting the trend toward personalization and localization of drug production.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of companies providing the infrastructure for cell and gene therapy are betting on the growth of the entire industry. The chart below shows the overall risk appetite. Is Orgenesis Inc. moving in sync with the market, or is its unique business model creating its own trend?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Orgenesis Inc.
The weekly performance of Orgenesis, a company seeking to decentralize cell therapy production, reflects the future of the industry. Its stock price is responding to the creation of a network of mobile production labs directly in hospitals, which could make treatment more accessible.
Weekly dynamics of market capitalization of the market segment - It med
Orgenesis provides services and technologies for the development and production of cell and gene therapies. It serves as a partner for biotech companies. This chart compares its performance with the sector and helps understand how the market views its "biotech infrastructure" business model.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Orgenesis is a biotech company working in the cutting-edge field of cell therapy. Shares of such innovative companies often move independently of the market. This chart will help you understand: does Orgenesis live in its own world of clinical trials, or are the overall market conditions and risk appetite influencing its stock price?
Market capitalization of the company, segment and market as a whole
ORGS - Market capitalization of the company Orgenesis Inc.
Orgenesis's market capitalization tells the story of a biotech company seeking to decentralize the production of cell and gene therapies, making them accessible directly to hospitals. Its volatile price chart reflects the market's assessment of this ambitious and potentially revolutionary business model.
ORGS - Share of the company's market capitalization Orgenesis Inc. within the market segment - It med
Orgenesis is a biotech company developing a decentralized model for cell and gene therapy production. Its share of the sector's market capitalization reflects its focus on innovation. The chart below shows how the market perceives its potential to make advanced treatments more accessible.
Market capitalization of the market segment - It med
Orgenesis is a biotech company seeking to decentralize and reduce the cost of cell and gene therapy production. The chart below shows the market capitalization of this cutting-edge sector. Its dynamics reflect both the enormous potential of these treatments and their prohibitive costs, which Orgenesis is trying to reduce.
Market capitalization of all companies included in a broad market index - GURU.Markets
Orgenesis is a biotech company working to decentralize the production of cell and gene therapies. Its market cap reflects the potential to make these complex drugs more accessible. Its growth reflects the industry's search for ways to scale the most advanced treatments.
Book value capitalization of the company, segment and market as a whole
ORGS - Book value capitalization of the company Orgenesis Inc.
Orgenesis's balance sheet is its network of partner clinics and capital invested in creating a decentralized platform for cell and gene therapy production. This is the tangible, infrastructural foundation for making expensive treatments more accessible. How has this innovative logistics asset evolved? The chart below shows its dynamics.
ORGS - Share of the company's book capitalization Orgenesis Inc. within the market segment - It med
Orgenesis is developing a cell and gene therapy platform by establishing a decentralized network of hospital-based manufacturing sites. The chart shows the share of these unique mobile and stationary manufacturing assets, reflecting its innovative business model.
Market segment balance sheet capitalization - It med
Orgenesis, a cell therapy company, uses a hybrid model. It is developing a platform for decentralized drug manufacturing, making it less capital-intensive than traditional manufacturers with massive manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
Orgenesis's capital is not in its drugs, but in its decentralized platform (POCare) for producing cell and gene therapies directly in hospitals. The company's assets are its technology and equipment. The chart shows how this "service" model compares in terms of assets compared to centralized manufacturing.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Orgenesis Inc.
Orgenesis is a cell therapy company. Its book value comes from its patents and manufacturing facilities. Its market valuation reflects the belief that its decentralized drug manufacturing model will be the future of personalized medicine. The chart reflects expectations for this business innovation.
Market to book capitalization ratio in a market segment - It med
Orgenesis Inc. aims to decentralize cell and gene therapy production by creating a network of mobile manufacturing labs. Its high valuation reflects the potential of its business model to make these expensive treatments more accessible.
Market to book capitalization ratio for the market as a whole
Orgenesis Inc., a cell therapy company, is a technology company whose value is based on patents and manufacturing platforms. This chart helps assess the market premium for cutting-edge biotechnologies with the potential to transform medicine, compared to the overall economic average.
Debts of the company, segment and market as a whole
ORGS - Company debts Orgenesis Inc.
Orgenesis, a biotech company building a decentralized network for cell and gene therapy production, is using capital to develop its unique business model. This chart shows how the company is funding its efforts to create accessible therapeutic solutions directly in hospitals, which requires investments in technology and partnerships.
Market segment debts - It med
Orgenesis is a biotech company building a decentralized platform for cell and gene therapy. This innovative model requires investment in technology and partnerships. This chart shows how the company is funding its unique strategy to make cutting-edge treatments more accessible.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Orgenesis Inc.
Orgenesis is a biotech company building a platform for the development and production of cell and gene therapies. This chart shows how the company leverages its decentralized manufacturing network. It helps assess the financial risks associated with implementing a new, capital-intensive business model in biopharma.
Market segment debt to market segment book capitalization - It med
Orgenesis provides services and technologies to accelerate the development and production of cell and gene therapies. The company aims to make these complex treatments more accessible. The chart shows debt trends in the biotech sector, providing context for assessing how Orgenesis finances its unique business model.
Debt to book value of all companies in the market
Orgenesis Inc., a cell and gene therapy company, is developing a decentralized manufacturing model, which could change the industry's cost structure. This chart shows the overall market leverage, allowing one to assess how the company's innovative business model impacts its capital requirements and leverage compared to traditional biotech companies.
P/E of the company, segment and market as a whole
P/E - Orgenesis Inc.
Orgenesis Inc. provides a decentralized platform for the development and production of cell and gene therapies. This chart shows how the market is valuing its "therapy-as-a-service" model. The trend reflects the belief that its approach can make these advanced treatments more accessible and affordable.
P/E of the market segment - It med
This industry chart for biotech companies serves as a benchmark for Orgenesis. It reflects the overall sentiment in the sector. Comparisons with it help understand how the market views Orgenesis's unique business model, which aims to create a decentralized network for the production of cell and gene therapies, potentially making treatments more accessible.
P/E of the market as a whole
Orgenesis is a biotech company building a decentralized network for the production of cell and gene therapies. Its valuation is a bet on its unique business model. It is not tied to general economic cycles, but depends on its ability to demonstrate that its manufacturing approach can make these complex treatments more accessible.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Orgenesis Inc.
A chart from Orgenesis Inc., a biotech company building a decentralized network for cell and gene therapy production, shows market expectations for its platform's growth. It reflects analysts' belief that its model will make advanced treatments more accessible and cost-effective.
%20P%2FE%20Orgenesis%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Orgenesis-Inc.&v=1772360387999 "Chart of the company's future (projected) P/E Orgenesis Inc.")
Future (projected) P/E of the market segment - It med
Orgenesis is a biotech company building a network of centers for the decentralized production of cell and gene therapies. The goal is to make these complex and expensive drugs more accessible. The chart shows forecasts for the biotech sector, helping to assess the market's confidence in Orgenesis's innovative service and manufacturing model.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-It-med&v=1772360388001 "Future (projected) P/E graph of the market segment - It med")
Future (projected) P/E of the market as a whole
Orgenesis Inc. provides a platform for the development and production of cell and gene therapies. The company aims to make these complex treatments more accessible. This graph of overall risk appetite shows how willing investors are to invest in companies building the infrastructure for the medicine of the future.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772360388003 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Orgenesis Inc.
Orgenesis Inc. provides a decentralized platform for the development and production of cell and gene therapies. Its goal is to make these expensive treatments more accessible. Profits come from partnerships with hospitals and biotech companies. This chart shows how the company is building a business around democratizing advanced medicine.
Profit of companies in the market segment - It med
Orgenesis is a biotech company building a decentralized network for the production of cell and gene therapies. This graph, which charts sector profitability, illustrates how the industry is working to make these complex treatments more accessible. Their point-of-care model aims to reduce costs and accelerate the production of personalized medications.
Overall market profit
Orgenesis Inc. provides services and technologies to accelerate the development and production of cell and gene therapies. The company operates at the heart of the biotech revolution. Demand for its services is directly dependent on activity in this sector. Economic growth, reflected in the graph, stimulates investment in biotech, leading to an increase in the number of Orgenesis clients.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Orgenesis Inc.
Orgenesis Inc. provides a decentralized platform for the development and production of cell and gene therapies. The company aims to make these complex treatments more accessible and affordable. This chart shows how analysts assess the success of its business model and the growing number of partnerships with biotech companies.
%20profit%20of%20the%20company%20Orgenesis%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Orgenesis-Inc.&v=1772360388006 "Graph of future (projected) profit of the company Orgenesis Inc.")
Future (predicted) profit of companies in the market segment - It med
Orgenesis Inc. is a biotech company aiming to make cell and gene therapies more accessible by creating a decentralized manufacturing network. Its model is similar to a "factory in a box," and growth depends on the adoption of its approach. This biotech chart reflects expectations for the growth of cell therapies and the search for ways to reduce their costs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-It-med&v=1772360388007 "Graph of future (predicted) profits of companies in a market segment - It med")
Future (predicted) profit of the market as a whole
Orgenesis Inc. provides a platform for the development and production of cell and gene therapies. Its business is growing alongside this innovative sector. The overall revenue forecast shown in the chart influences the amount of funding biotech companies are devoting to the development and commercialization of new treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772360388007 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Orgenesis Inc.
Orgenesis Inc. is a biotech company building a decentralized network for the development and production of cell and gene therapies. The chart shows how the market views its unique business model. It reflects its belief that its approach will make advanced treatments more accessible and cost-effective for hospitals.
P/S market segment - It med
Orgenesis Inc. is working to create a decentralized network for the development and production of cell and gene therapies, making them more accessible. The company's revenue depends on the success of this innovative model. This chart reflects the average valuation in the sector, helping to understand how investors view Orgenesis's potential to change the paradigm of advanced drug manufacturing.
P/S of the market as a whole
Orgenesis is a biotech company building a decentralized network for the development and production of cell and gene therapies. Its goal is to make these cutting-edge treatments more accessible. This chart, showing the average market revenue estimate, helps us understand the premium investors are willing to pay for this innovative business model, which has the potential to transform the entire industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Orgenesis Inc.
Orgenesis is a biotech company building a decentralized network for the production of cell and gene therapies. Its goal is to make these expensive treatments more accessible. This chart reflects investors' belief that its business model can change the manufacturing paradigm and accelerate the adoption of cutting-edge therapies.
%20P%2FS%20Orgenesis%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Orgenesis-Inc.&v=1772360388011 "The graph of the company's future (projected) P/S Orgenesis Inc.")
Future (projected) P/S of the market segment - It med
Orgenesis Inc. provides a decentralized platform for the development and production of cell and gene therapies, aiming to make these advanced treatments more accessible and cost-effective. This chart shows the average estimated future sales in the biotech sector, helping to understand how the market views Orgenesis's innovative business model.
%20P%2FS%20market%20segment%20graph%20-%20It%20med&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-It-med&v=1772360388012 "Future (projected) P/S market segment graph - It med")
Future (projected) P/S of the market as a whole
Orgenesis Inc. provides a decentralized platform for the development and production of cell and gene therapies. This chart shows investor revenue growth expectations. Orgenesis's approach aims to make these complex and expensive treatments more accessible by locating manufacturing directly in hospitals.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772360388013 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Orgenesis Inc.
This chart illustrates the revenue of Orgenesis Inc., a biotech company that provides services and technologies to accelerate the development and production of cell and gene therapies. Revenue is generated from contracts with other pharmaceutical companies. The trend shows the demand for its decentralized drug manufacturing platform.
Sales of companies in the market segment - It med
Orgenesis Inc. provides a decentralized platform for the development and production of cell and gene therapies. This graph reflects the growth of the biotech market. Orgenesis's approach to creating affordable treatments directly in hospitals has the potential to dramatically reduce the cost and accelerate the adoption of these advanced therapies, democratizing access.
Overall market sales
Orgenesis Inc. provides services for the development and production of cell and gene therapies. Demand for its platform depends on activity in the biotech sector. This total revenue chart reflects the state of the economy, which influences investment in the development of advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Orgenesis Inc.
Orgenesis is creating a decentralized network for the production of cell and gene therapies, making them more accessible. Future revenue depends on the growth of the entire industry and the number of partners using its platform. The graph reflects the expected development of this cutting-edge medical sector.
%20sales%20of%20the%20company%20Orgenesis%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Orgenesis-Inc.&v=1772360388019 "Schedule of future (projected) sales of the company Orgenesis Inc.")
Future (projected) sales of companies in the market segment - It med
Orgenesis is a biotech company creating a decentralized network for the development and production of cell and gene therapies. Its goal is to make these complex and expensive treatments more accessible to patients. This graph shows the forecast for the entire medical technology market, where Orgenesis offers an innovative business model.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-It-med&v=1772360388020 "Schedule of future (projected) sales of companies in the market segment - It med")
Future (projected) sales of the market as a whole
Orgenesis is a biotech company aiming to make cell and gene therapies more accessible by creating a decentralized network for hospital-based manufacturing of these drugs. This graph, reflecting investments in cutting-edge medicine, is an indicator of demand for solutions that can reduce the enormous cost of innovative treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772360388021 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Orgenesis Inc.
Orgenesis is a biotech company building a decentralized network for the production of cell and gene therapies directly in hospitals. The profitability of its model depends on the implementation of this innovative point-of-care concept. This chart shows the costs of creating this global platform, which could make advanced treatments more accessible.
Market segment marginality - It med
Orgenesis is developing a decentralized model for the production and delivery of cell and gene therapies, aiming to make them more accessible. Profitability depends on the adoption of this point-of-care concept by hospitals and partners. This chart reflects investments in creating new infrastructure for personalized medicine and its operational results.
Market marginality as a whole
Orgenesis is a biotech company creating a decentralized network for the development and production of cell and gene therapies. Their goal is to make these expensive treatments more accessible. Against this backdrop, reflecting the current economy, Orgenesis is building the infrastructure for the medicine of the future. Their success depends on the adoption of their point-of-service model.
Employees in the company, segment and market as a whole
Number of employees in the company Orgenesis Inc.
Orgenesis is developing a decentralized model for manufacturing cell and gene therapies. Its team consists of scientists and manufacturing specialists. This graph reflects its efforts to establish a network of small manufacturing centers directly within hospitals, a key differentiator.
Share of the company's employees Orgenesis Inc. within the market segment - It med
Orgenesis is developing a decentralized model for producing cell and gene therapies, creating a network of mini-laboratories directly within hospitals. This chart reflects its unique workforce. It shows the size of the team that not only conducts research but also implements this complex point-of-care model worldwide, making therapies more accessible.
Number of employees in the market segment - It med
Orgenesis Inc. is a biotechnology company developing a platform for the decentralized production of cell and gene therapies. This chart illustrates employment trends in the advanced drug manufacturing sector. The growing number of engineers and biologists reflects the desire to make expensive cell therapies more accessible by moving their production directly to clinics.
Number of employees in the market as a whole
Orgenesis Inc. provides services for the development and production of cell and gene therapies. Its business is growing alongside this innovative industry. Overall economic growth, visible in this chart, supports high levels of investment in biotechnology, ensuring a steady flow of clients for Orgenesis's contract manufacturing.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Orgenesis Inc. (ORGS)
Orgenesis Inc. is working to decentralize cell and gene therapy production by creating mobile laboratories (OMPULs) directly in hospitals. This is a unique business model. The chart shows the market value of this approach. The high cost per employee reflects Orgenesis's position as a technology and logistics company, not a traditional drug manufacturer with a large workforce in a single plant.
%20of%20the%20company%20Orgenesis%20Inc.%20(ORGS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Orgenesis-Inc.-ORGS&v=1772360388036 "Chart of market capitalization per employee (in thousands of dollars) of the company Orgenesis Inc. (ORGS)")
Market capitalization per employee (in thousands of dollars) in the market segment - It med
Orgenesis provides services and technologies to accelerate the development and production of cell and gene therapies. It serves as a kind of outsourcing platform for biotech companies. This chart shows how the market views its unique business model and its ability to improve the efficiency of the entire cell therapy industry.
%20by%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-It-med&v=1772360388036 "Market capitalization per employee (in thousands of dollars) by market segment - It med")
Market capitalization per employee (in thousands of dollars) for the overall market
Orgenesis Inc. provides a decentralized platform for the development and production of cell and gene therapies. The chart shows the company's valuation in the cutting-edge biotech space. It reflects how the market views their business model, which aims to make these complex treatments more accessible and cost-effective.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772360388037 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Orgenesis Inc. (ORGS)
Orgenesis is a biotech company that doesn't create drugs itself, but provides other companies and hospitals with a platform ("point of care") for developing and manufacturing cell and gene therapies. It's a B2B service. This chart shows how successfully their team is implementing these "mini-factories" and generating revenue from the services.
%20Chart%20Orgenesis%20Inc.%20(ORGS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Orgenesis-Inc.-ORGS&v=1772360388038 "Company Profit Per Employee (in thousands of dollars) Chart Orgenesis Inc. (ORGS)")
Profit per employee (in thousands of dollars) in the market segment - It med
Orgenesis is a biotech company with a unique model. They are creating a decentralized point-of-care (POCare) network for the production of cell and gene therapies directly in hospitals. This figure reflects the investment in creating this complex service and technology platform.
%20in%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-It-med&v=1772360388039 "Chart of profit per employee (in thousands of dollars) in the market segment - It med")
Profit per employee (in thousands of dollars) for the market as a whole
Orgenesis Inc. is a biotech company providing a platform (POCare) for the decentralized production of cell and gene therapies (directly in hospitals). It's an "R&D-as-a-Service." This chart demonstrates how in-demand and profitable their unique model (selling "mini-labs") is.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772360388042 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Orgenesis Inc. (ORGS)
Orgenesis provides services and technologies for the development and production of cell and gene therapies. This chart demonstrates the demand for its platform. The growth in revenue per employee reflects contracts with biotech companies and hospitals, allowing them to accelerate the development and production of cutting-edge drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Orgenesis-Inc.-ORGS&v=1772360388044 "Sales chart per company employee Orgenesis Inc. (ORGS)")
Sales per employee in the market segment - It med
Orgenesis (ORGS) works in the field of cell therapy, but with a unique approach. They create decentralized manufacturing "micro-factories" (OMPULs) directly in hospitals. This graph shows how much revenue (from services and equipment sales) each employee generates. This measures the productivity of their innovative business model.
Sales per employee for the market as a whole
Orgenesis (ORGS) provides services and technologies to accelerate the development of cell and gene therapies. It's a B2B service for biotech companies. The company helps others develop and manufacture drugs. This chart shows how effectively the company's scientists and technicians generate service revenue by servicing contracts with other pharmaceutical companies.
Short shares by company, segment and market as a whole
Shares shorted by company Orgenesis Inc. (ORGS)
Orgenesis provides services and technologies (CDMO) for the development of cell and gene therapies. This chart shows bearish bets. Investors likely expect the slowdown in the biotech sector and reduced venture funding to lead to reduced demand for the company's services from its startup clients.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Orgenesis-Inc.-ORGS&v=1772360388050 "Short Shares Chart for the Company Orgenesis Inc. (ORGS)")
Shares shorted by market segment - It med
Orgenesis Inc. is transforming the cell and gene therapy sector, moving from centralized manufacturing to a decentralized, point-of-care model. This chart measures the overall bearish bets on the entire cell therapy industry. It reveals the market's collective doubts about the scalability, cost, and regulatory approval of these complex treatments across the sector.
Shares shorted by the overall market
Orgenesis operates at the intersection of biotech and IT, creating platforms for cell therapy. It's a business of the "future." This chart shows the rise of general fear. When investors panic, they stop "buying the future." They see an R&D company burning through cash and flee, fearing that a crisis will dry up the flow of capital to science.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Orgenesis Inc. (ORGS)
Orgenesis Inc. is a biotech company developing a platform for the decentralized production of cell therapies. It's an ambitious bet on the "hospital of the future." This oscillator measures investor excitement around their platform, showing it as "overheated" (above 70) on positive partnership news or "oversold" (below 30) in anticipation of implementation.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Orgenesis-Inc.-ORGS&v=1772360388053 "RSI 14 indicator chart for the company's stock Orgenesis Inc. (ORGS)")
RSI 14 Market Segment - It med
Orgenesis (ORGS) is a biotech company seeking to decentralize cell therapy production. Their O-CUVs platform enables point-of-care drug development. This chart reflects the overall sentiment in the medical IT and biotech services sector. It helps assess whether this entire innovative segment is overheated.
RSI 14 for the overall market
Orgenesis (ORGS) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ORGS (Orgenesis Inc.)
Orgenesis (ORGS) is a biotech company developing a decentralized point-of-care (O-RAN) model for producing cell and gene therapies directly in hospitals. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of this innovative business model and its potential to transform the cell therapy industry.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ORGS-Orgenesis-Inc.&v=1772360388057 "A chart showing analyst consensus forecasts for the expected stock price. ORGS (Orgenesis Inc.)")
The difference between the consensus estimate and the actual stock price ORGS (Orgenesis Inc.)
Orgenesis (ORGS) is the "democratization" of cell therapy. Their platform (POCare) is not a "factory," but a "micro-factory" in a hospital for creating "fresh" drugs at the patient's bedside. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this "distributed" R&D model.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ORGS-Orgenesis-Inc.&v=1772360388060 "A chart showing the difference between the consensus forecast and the actual stock price. ORGS (Orgenesis Inc.)")
Analyst consensus forecast for stock prices by market segment - It med
Orgenesis is a cell therapy "factory." The company creates "mobile" mini-laboratories (POCare), which allow hospitals to produce cell-based therapies "on-site." This chart reflects analysts' general expectations for the *entire* medical IT sector. It shows whether experts believe in the "decentralization" of drug production.
Analysts' consensus forecast for the overall market share price
Orgenesis (ORGS) is a cell therapy "factory in a box." They don't make drugs, but rather create "mini-laboratories" (OMPULs) that allow hospitals to produce cell therapy on-site. This chart shows the overall risk appetite. It reflects the market's willingness to fund "infrastructure" startups for the "medicine of the future."
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Orgenesis Inc.
Orgenesis is a cell therapy factory. They don't treat patients; their specialty is automation (O-CART) and decentralization: they sell (B2B) micro-factories (software and hardware) to hospitals so they can manufacture cell therapies (CAR-T) at the patient's bedside (instead of centralized production). This chart is a summary indicator of their B2B model. It reflects their uneven order book.
AKIMA Market Segment Index - It med
Orgenesis (ORGS) is the IT-medicine for biotech. They don't treat patients, but rather provide a B2B platform (point-of-care) for producing cell and gene therapies directly in hospitals, rather than in factories. This chart compares their composite index to the sector, showing how their decentralized manufacturing model outperforms their competitors.
The AKIM Index for the overall market
Orgenesis is a global biotech company providing decentralized cell and gene therapy development and manufacturing services (POCare). This chart, which reflects the market average, provides context. It helps assess how this service partner for innovative medicine compares to overall macroeconomic trends.
